A Pilot Study for Return of Individual Pharmacogenomic Results to Population-Based Cohort Study Participants.
Pharmacogenomics
Population-based cohort study
Return of genomic results
Journal
JMA journal
ISSN: 2433-3298
Titre abrégé: JMA J
Pays: Japan
ID NLM: 101769797
Informations de publication
Date de publication:
15 Apr 2022
15 Apr 2022
Historique:
received:
18
08
2021
accepted:
01
12
2021
entrez:
25
5
2022
pubmed:
26
5
2022
medline:
26
5
2022
Statut:
ppublish
Résumé
Pharmacogenomic (PGx) testing results provide valuable information on drug selection and appropriate dosing, maximization of efficacy, and minimization of adverse effects. Although the number of large-scale, next-generation-sequencing-based PGx studies has recently increased, little is known about the risks and benefits of returning PGx results to ostensibly healthy individuals in research settings. Single-nucleotide variants of three actionable PGx genes, namely, Whereas the majority of participants were unfamiliar with the term PGx, and none had undergone PGx testing before the study, more than 80% of the participants felt that they could acquire basic PGx knowledge sufficient to understand their genomic results and were satisfied with their potential benefit and use in future prescriptions. On the other hand, some felt that the PGx concepts or terminology was difficult to fully understand and suggested that in-person return of the results was desirable. These results collectively suggest possible benefits of returning preemptive PGx information to ostensibly healthy cohort participants in a research setting.
Identifiants
pubmed: 35611229
doi: 10.31662/jmaj.2021-0156
pmc: PMC9090545
doi:
Types de publication
Journal Article
Langues
eng
Pagination
177-189Informations de copyright
Copyright © Japan Medical Association.
Déclaration de conflit d'intérêts
None
Références
Gastroenterology. 2016 Jul;151(1):51-69.e14
pubmed: 27102658
Nat Commun. 2015 Aug 21;6:8018
pubmed: 26292667
J Nerv Ment Dis. 2002 Mar;190(3):175-82
pubmed: 11923652
NPJ Genom Med. 2020 May 4;5:19
pubmed: 32377377
Nihon Koshu Eisei Zasshi. 1990 Nov;37(11):913-8
pubmed: 2132363
World J Gastroenterol. 2014 Apr 28;20(16):4483-90
pubmed: 24782601
J Biochem. 2019 Feb 1;165(2):139-158
pubmed: 30452759
Hum Genome Var. 2019 Jun 18;6:28
pubmed: 31240104
Tohoku J Exp Med. 2019;248(1):19-25
pubmed: 31080195
Bioethics. 2015 Feb;29(2):82-90
pubmed: 24471556
Life Sci. 1996;59(20):1711-5
pubmed: 8890945
JMA J. 2019 Sep 4;2(2):113-122
pubmed: 33615021
Tohoku J Exp Med. 2019;248(1):45-55
pubmed: 31130587
Hum Genome Var. 2020 Sep 18;7:27
pubmed: 33014404
J Epidemiol. 2016 Sep 5;26(9):493-511
pubmed: 27374138
Clin Pharmacol Ther. 2014 Oct;96(4):482-9
pubmed: 24960519
J Gastroenterol. 2018 Feb;53(2):172-180
pubmed: 29192347
Bioethics. 2006 Feb;20(1):24-36
pubmed: 16680905
J Epidemiol. 2021 Jan 5;31(1):65-76
pubmed: 31932529
BMC Med Educ. 2019 Aug 2;19(1):297
pubmed: 31375111
J Epidemiol. 2022 Feb 5;32(2):69-79
pubmed: 33041318
Lancet. 2019 Aug 10;394(10197):521-532
pubmed: 31395440
Mayo Clin Proc. 2017 Nov;92(11):1711-1722
pubmed: 29101939
J Med Genet. 2003 Aug;40(8):632-6
pubmed: 12920080
Genet Med. 2017 Jul;19(7):819-825
pubmed: 28055020
Pharmacogenomics. 2018 Mar;19(4):321-331
pubmed: 29469671
J Mol Diagn. 2017 Jul;19(4):561-566
pubmed: 28502727
Pharmacogenomics J. 2016 Jun;16(3):280-5
pubmed: 26076924
J Hum Genet. 2022 Jan;67(1):9-17
pubmed: 34234266
Patient Educ Couns. 2021 Feb;104(2):242-249
pubmed: 32919825
Clin Pharmacol Ther. 2014 Apr;95(4):376-82
pubmed: 24458010
PLoS One. 2012;7(2):e31276
pubmed: 22384008
Genome Med. 2015 Jul 03;7(1):67
pubmed: 26221186
J Toxicol Sci. 1998 Jul;23 Suppl 2:129-31
pubmed: 9760448
Clin Pharmacol Ther. 2004 Jun;75(6):495-500
pubmed: 15179404
Genes Cells. 2018 Jun;23(6):406-417
pubmed: 29701317
Pharmacogenomics. 2012 Jun;13(8):935-49
pubmed: 22676197
J Clin Pharm Ther. 2019 Aug;44(4):508-524
pubmed: 30980418
J Gastroenterol. 2018 Sep;53(9):1065-1078
pubmed: 29923122
Psychol Med. 2002 Aug;32(6):959-76
pubmed: 12214795
Int J Epidemiol. 2020 Feb 1;49(1):18-19m
pubmed: 31504573